Frontiers in medicine · 2026
Real-world effectiveness of vonoprazan-based regimen versus rabeprazole-based dual therapy for Helicobacter pylori eradication in a high-resistance, multi-ethnic region: a multicenter study in Guizhou, China.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Huang Yurong, Zheng Juan, Yang Zhengyi, Li Daili, Wu Hua, Chen Wenzhong, Wang Wenjuan, Gan Min, Shi Changmei, Xie Dongmei, Zhan Canyu, Song Gengqing, Yang Jie
Аннотация
INTRODUCTION: While vonoprazan-amoxicillin dual therapy has achieved > 90% eradication rates for Helicobacter pylori (H. pylori) in clinical trials, its effectiveness in "real-world" regions with high primary antibiotic resistance and ethnic diversity remains under-verified. This multicenter study evaluated whether simplified vonoprazan-based regimens can overcome these regional barriers compared to standard rabeprazole-based dual therapy.
METHODS: This retrospective analysis (April 2022-November 2023) included 598 H. pylori-positive outpatients from 10 centers across 8 prefectures of Guizhou. Patients received one of four 14-day therapies: Group A (vonoprazan 20 mg b.i.d. + amoxicillin 1 g t.i.d.), Group B (vonoprazan 20 mg q.d. + amoxicillin 1 g t.i.d.), Group C (vonoprazan 20 mg q.d. + amoxicillin 1 g b.i.d. + furazolidone 100 mg b.i.d. + colloidal bismuth pectin 100 mg t.i.d.), Group D (rabeprazole 20 mg b.i.d. + amoxicillin 1 g t.i.d.). The primary endpoint was the eradication rate, confirmed by 13C/14C urea breath tests at least 4 weeks post-treatment.
RESULTS: After excluding patients lost to follow-up and those with poor compliance, the eradication rates were 87.2% (Group A), 81.4% (Group B), 82.1% (Group C), and 71.5% (Group D). Group A achieved a significantly higher eradication rate than Group D (p < 0.001), while no other significant between-group differences were observed. However, none of the regimens reached the 90% "optimal" threshold. Notably, the once-daily (q.d.) vonoprazan regimens (Groups B and C) failed to reach the 85% clinical acceptability threshold in this specific geographic cohort. No significant association was observed between treatment success and age, sex, or ethnicity.
CONCLUSION: In the high-resistance environment of Guizhou, vonoprazan-based regimens are significantly more effective than traditional rabeprazole-based dual therapy, yet they face unique regional challenges. The failure of q.d. vonoprazan dosing and the sub-90% success rate of b.i.d. dosing suggest that in regions with extreme resistance and high ethnic diversity, standard global protocols may require further optimization.
METHODS: This retrospective analysis (April 2022-November 2023) included 598 H. pylori-positive outpatients from 10 centers across 8 prefectures of Guizhou. Patients received one of four 14-day therapies: Group A (vonoprazan 20 mg b.i.d. + amoxicillin 1 g t.i.d.), Group B (vonoprazan 20 mg q.d. + amoxicillin 1 g t.i.d.), Group C (vonoprazan 20 mg q.d. + amoxicillin 1 g b.i.d. + furazolidone 100 mg b.i.d. + colloidal bismuth pectin 100 mg t.i.d.), Group D (rabeprazole 20 mg b.i.d. + amoxicillin 1 g t.i.d.). The primary endpoint was the eradication rate, confirmed by 13C/14C urea breath tests at least 4 weeks post-treatment.
RESULTS: After excluding patients lost to follow-up and those with poor compliance, the eradication rates were 87.2% (Group A), 81.4% (Group B), 82.1% (Group C), and 71.5% (Group D). Group A achieved a significantly higher eradication rate than Group D (p < 0.001), while no other significant between-group differences were observed. However, none of the regimens reached the 90% "optimal" threshold. Notably, the once-daily (q.d.) vonoprazan regimens (Groups B and C) failed to reach the 85% clinical acceptability threshold in this specific geographic cohort. No significant association was observed between treatment success and age, sex, or ethnicity.
CONCLUSION: In the high-resistance environment of Guizhou, vonoprazan-based regimens are significantly more effective than traditional rabeprazole-based dual therapy, yet they face unique regional challenges. The failure of q.d. vonoprazan dosing and the sub-90% success rate of b.i.d. dosing suggest that in regions with extreme resistance and high ethnic diversity, standard global protocols may require further optimization.